Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study

Abstract

Background: Alopecia areata (AA) is an autoimmune hair loss condition that affects people of all ages. Early age of onset and prolonged disease duration indicate poor prognosis. Janus kinase inhibitors are being investigated in phase 3 clinical trials in adolescents and adults with AA. Objective: To evaluate the use of oral tofacitinib in pre-adolescent patients with AA. Methods: A retrospective review of case records of all pre-adolescent patients with AA treated with oral tofacitinib in a single center between 2018 and 2019. Results: Fourteen patients were identified, aged 7 to 11 years. Nine patients experienced clinically significant improvement in their SALT (Severity of Alopecia Tool) ..